Cosmetic-Grade Exosome Compliant Raw Material Production

Q: How do you handle endotoxin in Gram-negative OMV production?

Gram-negative outer membrane vesicles inherently contain lipopolysaccharide (LPS). Our cosmetic-grade purification protocols apply multi-step endotoxin reduction including polymyxin B affinity chromatography, anion-exchange separation, and detergent-based LPS stripping, targeting residual endotoxin levels below 0.5 EU/mL. For strains where endotoxin cannot be reduced to cosmetic thresholds, we recommend transitioning to Gram-positive probiotic CMV platforms that lack LPS entirely.

Q: Can you produce mEVs from client-provided proprietary strains?

Yes. Client strains are accepted under confidentiality agreements with secure strain banking. We perform full safety profiling on every client strain before compliant production begins. Proprietary fermentation parameters and production protocols are documented for technology transfer, ensuring ingredient IP remains with the brand owner.

Q: What is the difference between cosmetic-grade and GMP-grade production?

Cosmetic-grade production meets cosmetic ingredient manufacturing standards with controlled fermentation, validated purification, defined purity thresholds, and regulatory documentation for INCI registration and safety assessment. GMP-Grade production adds pharmaceutical-level quality assurance including validated cleaning procedures, environmental monitoring, change control documentation, and QA release authority. Cosmetic-grade is sufficient for topical ingredient registration; GMP-grade is required for injectable or therapeutic claims.

Q: Do you provide stability testing for cosmetic ingredient registration?

Yes. We conduct real-time stability testing at 25°C/60% RH and accelerated stability testing at 40°C/75% RH per ICH-aligned conditions, monitoring particle retention, protein integrity, endotoxin stability, and sterility over defined time points. Stability data packages are formatted for inclusion in regulatory submissions supporting declared shelf-life claims.

Q: What INCI name conventions apply to microbial exosome ingredients?

INCI naming for microbial-derived vesicle ingredients follows the organism-based convention (e.g., “Lactobacillus ferment extracellular vesicles” or “Bifidobacterium lysate extracellular vesicles”). We assist clients in proposing appropriate INCI nomenclature and preparing the supporting documentation required for International Nomenclature Committee review and registration.

Q: How do you ensure batch-to-batch consistency for cosmetic ingredient supply?

Locked fermentation protocols, standardized purification sequences, and defined QC release criteria ensure reproducible batch output. Inter-batch CV ≤20% for particle concentration, size distribution, and key purity metrics across three consecutive production batches. Deviation investigations and corrective actions are documented per cosmetic ingredient quality management standards.

Inquiry

OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs

Overview

Cosmetic brands seeking to incorporate microbial extracellular vesicles (mEVs) into skincare formulations face a regulatory landscape that demands far more than research-scale production. Ingredient registration, safety documentation, purity thresholds, and traceability requirements transform a biologically interesting vesicle into a market-ready cosmetic raw material—a transition that most academic protocols cannot navigate.

At Creative BioMart Microbe, we provide Cosmetic-Grade exosome compliant raw material production services that convert microbial vesicle batches into regulatory-ready cosmetic ingredients. Every production campaign is executed under controlled conditions aligned with cosmetic ingredient manufacturing standards, with full documentation packages supporting INCI registration, and EU Cosmetic Regulation compliance special-use cosmetic ingredient dossiers. Our platform covers probiotic-derived, fungal-derived, and engineered microbial vesicles, each processed through validated workflows that address cell wall architecture differences, membrane composition variability, and cosmetic-specific contaminant limits.

Unlike mammalian exosome CROs that apply stem-cell protocols to microbial systems, our production infrastructure is purpose-built for microbial biologies. Fermentation, isolation, and purification steps are optimized for the distinct vesicle biogenesis pathways of Gram-positive cytoplasmic membrane vesicles, Gram-negative outer membrane vesicles, and fungal extracellular vesicles. Clients receive not just vesicle batches, but the complete compliance documentation portfolio required to register mEVs as cosmetic active ingredients worldwide.

Figure 1. Compliant raw material production workflow for cosmetic-grade microbial exosomes, from regulatory consultation through batch QC release to documentation delivery.

Services

Production Workflow

Our cosmetic-grade raw material production follows a six-stage compliance pathway that ensures every batch meets cosmetic ingredient regulatory thresholds before release. Each stage generates auditable documentation, enabling clients to compile registration dossiers from verified production records.

Inquiry

Production Services

Three-dimensional illustration of a laboratory safety profiling station showing a petri dish with probiotic colonies, an antibiotic resistance screening plate with clear zones, and a hemolytic activity test tube with blood agar substrate, all arranged on a sterile white surface with a magnifying inspection lens hovering above.

Cosmetic-Grade Strain Verification & Safety Profiling

Every production strain undergoes identity confirmation by 16S rRNA sequencing, antibiotic resistance screening, hemolytic activity testing, and virulence factor assessment. Only strains passing all safety criteria enter compliant fermentation. Documentation includes taxonomic certificates and safety clearance reports aligned with cosmetic ingredient registration requirements.

Three-dimensional illustration of a stainless-steel benchtop bioreactor vessel with a digital control panel displaying green parameter readouts, pale amber culture medium visible through a sight glass, and a connected data logger unit recording process parameters, positioned on a clean white laboratory surface beside a sterile media bottle.

Compliant Fermentation & Scalable Production

We operate controlled fermentation campaigns under documented process parameters (media composition, pH, temperature, dissolved oxygen, agitation). Scale ranges from bench-top (5–50 L) to pilot-scale (50–500 L), with process analytical technology monitoring and batch records traceable to raw material certificates. Every campaign produces cosmetics-grade harvest material with defined yield and purity baselines.

Three-dimensional illustration showing a vertical chromatography column with visible resin bed and eluate collection vials below, beside a centrifuge rotor in top-down cross-section view, and an ultrafiltration membrane cassette with flow channels, all arranged in a purification sequence on a sterile white surface.

Cosmetic-Grade Purification & Contaminant Removal

Purification protocols target cosmetic-specific purity thresholds: endotoxin levels below 0.5 EU/mL for Gram-negative OMVs, lipoteichoic acid removal for Gram-positive CMVs, residual DNA clearance, and heavy metal screening. Multi-step purification combines ultrafiltration, density gradient separation, and size-exclusion chromatography, validated for contaminant reduction and vesicle recovery at each stage.

Three-dimensional illustration of a QC release testing station featuring a nanoparticle tracking analysis instrument displaying a bell-curve particle size histogram on its screen, a plate reader with a 96-well plate showing color-gradient wells, and a sealed certificate document with a gold compliance seal, all on a white laboratory surface.

Batch QC Release & Characterization

Each production batch undergoes comprehensive release testing: particle size and concentration by NTA, morphology by TEM, surface charge by zeta potential, protein profile by SDS-PAGE, endotoxin quantification, residual DNA detection, and microbial sterility verification. Release criteria are documented in batch-specific certificates of analysis, with intra-batch CV ≤15% and inter-batch CV ≤20% for all quantitative endpoints.

Compliance Thresholds & Specifications

Cosmetic-Grade Purity & Safety Thresholds

Parameter	Cosmetic-Grade Threshold	Testing Method
Endotoxin (Gram-negative OMVs)	<0.5 EU/mL	LAL chromogenic assay
Lipoteichoic acid (Gram-positive CMVs)	<1 μg/mL residual	ELISA quantitative detection
Residual DNA	<10 ng/mL	PicoGreen fluorometric assay
Heavy metals (Pb, As, Cd, Hg)	Below EU Cosmetic Regulation limits	ICP-MS multi-element screening
Microbial sterility	No viable organisms detected	Sterility testing
Particle concentration	10⁹–10¹² particles/mL	Nanoparticle tracking analysis
Protein-to-particle ratio	≤1 μg per 10⁹ particles	BCA assay + NTA cross-validation
Polydispersity index	<0.2	Dynamic light scattering

Regulatory Documentation Deliverables

INCI name registration application: proposed nomenclature, ingredient definition, manufacturing process description, and supporting characterization data.
EU SCCS safety assessment dossier: physicochemical specification, impurity profile, toxicological evaluation, exposure assessment, and margin of safety calculation.
Batch certificate of analysis: particle concentration, size distribution, purity metrics, endotoxin level, sterility confirmation, and heavy metal screening results for each released batch.
Stability data package: real-time and accelerated stability testing results per ICH-aligned conditions, supporting declared shelf-life and storage specifications.
Traceability documentation: strain origin certificate, raw material certificates, fermentation batch records, purification process logs, and QC release chain linked by batch number.

Turnaround Time

Service Component	Timeline
Strain verification and safety profiling	2–3 weeks
Compliant fermentation campaign (bench-scale)	3–5 weeks
Compliant fermentation campaign (pilot-scale)	5–8 weeks
Cosmetic-grade purification protocol development	3–4 weeks
Batch QC release testing	1–2 weeks per batch
Regulatory documentation compilation	2–4 weeks
Complete raw material production package	12–20 weeks
Expedited timeline	+50% fee, 40% time reduction

Timeline may vary based on strain type, production scale, and regulatory documentation scope.

Sample Requirements

Required Information	Optional Information	Not Accepted
Target microbial species or genus Strain source (culture collection, client-provided, or Creative BioMart Microbe-sourced) Intended cosmetic application category (skincare, haircare, sun protection) Target regulatory market (EU, US FDA cosmetic, etc.) Desired production scale and batch quantity Intended product format (serum, cream, lotion, mask)	Prior fermentation or characterization data Existing INCI name proposal Specific purity thresholds beyond standard Reference competitor ingredient specifications Brand-specific documentation format requirements Target shelf-life specifications	Pathogenic or uncharacterized strains without safety profiles Strains with documented antibiotic resistance transfer risk Genetically modified organisms without proper regulatory clearance documentation Contaminated or mixed microbial cultures Samples without cold-chain shipping documentation Mammalian-derived exosome samples (out of platform scope)

Recommended Sample Quantity by Service:

Service	Minimum	Recommended
Strain verification and safety profiling	Glycerol stock or agar stab	1 mL glycerol stock + 2 agar plates
Bench-scale compliant fermentation	1 verified strain	2–3 strains for comparison
Pilot-scale compliant production	Bench-scale validated protocol	Completed bench-scale campaign data
Cosmetic-grade purification development	500 mL culture supernatant	1–2 L culture supernatant
Regulatory documentation compilation	Completed QC release report	Full production campaign records

Storage & Shipping: Ship microbial strains as glycerol stocks on dry ice with cold-chain documentation. Provide strain origin, isolation history, and any prior safety data. For purified mEV samples, ship in sterile PBS on dry ice with certificate of analysis. Include target product specifications and regulatory requirements for documentation projects.

Inquiry

Our Advantages

Microbial-Native Compliance Protocols — Our purification and QC workflows address the unique contaminant profiles of microbial vesicles: lipoteichoic acid clearance for Gram-positive CMVs, endotoxin reduction for Gram-negative OMVs, and glucan removal for fungal EVs—contaminants that mammalian exosome protocols never encounter.
Regulatory-Ready Documentation — Every production campaign generates auditable records formatted for INCI registration, and EU SCCS submission, eliminating the documentation gap between vesicle production and market entry.
Tiered Compliance Upgrade Path — Clients can begin with Research-Grade characterization and upgrade to Cosmetic-Grade or GMP-Grade manufacturing without redundant revalidation, leveraging existing strain safety and fermentation data across compliance tiers.
Strain Bank & IP Protection — Client strains are stored under confidentiality agreements with secure banking, and proprietary fermentation protocols are documented for technology transfer, ensuring that ingredient IP remains with the brand.
Cosmetic-Specific Purity Thresholds — We apply purity criteria derived from cosmetic ingredient regulations, not pharmaceutical GMP limits, ensuring that mEV batches meet the safety thresholds relevant to topical application rather than injectable drug standards.

Applications

Centralized square composition showing a translucent cosmetic serum bottle as the primary subject, with microscopic exosome vesicles floating in a teal-tinted liquid medium inside the bottle, surrounded by small fibroblast cell icons showing collagen fiber production indicators, on a clean white background.

mEV Anti-Aging Serum Ingredients

Compliant probiotic-derived mEV raw materials for collagen-boosting and wrinkle-reduction serum formulations.

Centralized square composition showing a cosmetic cream jar as the primary subject, with a cross-section of skin layers showing tight junction reinforcement by vesicle penetration, surrounded by keratinocyte cell icons with barrier integrity markers, on a clean white background.

mEV Skin Barrier Repair Cream Ingredients

Regulatory-ready mEV ingredients for barrier-strengthening and hydration-enhancing face cream formulations.

Centralized square composition showing a transparent toner bottle as the primary subject, with inflammatory cytokine signal indicators being suppressed by vesicle-mediated modulation, surrounded by macrophage cell icons showing polarization shift markers, on a clean white background.

mEV Anti-Inflammatory Toner Ingredients

Compliant mEV raw materials for sensitive-skin toner formulations targeting inflammation suppression and redness reduction.

Centralized square composition showing a scalp treatment serum bottle as the primary subject, with a hair follicle cross-section showing vesicle penetration into the dermal papilla, surrounded by small keratinocyte and melanocyte icons with regeneration indicators, on a clean white background.

mEV Hair & Scalp Treatment Ingredients

Compliant mEV ingredients for hair growth stimulation and scalp health restoration in premium haircare formulations.

Case Study

Case Study 1: Characterization and Cellular Uptake of Lactobacillus druckerii-Derived Extracellular Vesicles

Researchers isolated extracellular vesicles from Lactobacillus druckerii (LDEVs) and performed comprehensive characterization including transmission electron microscopy (TEM) imaging confirming typical spherical vesicle morphology, nanoparticle tracking analysis (NTA) determining particle size distribution and concentration, and cellular uptake verification demonstrating that PKH-26-labeled LDEVs were taken up by hypertrophic scar fibroblasts. The characterization pipeline demonstrated production of well-defined microbial vesicles with reproducible physicochemical properties, while the uptake data confirmed delivery potential. This study exemplifies the multi-parameter characterization and cellular internalization validation required for standardized microbial extracellular vesicle production.

Figure 2. Characterization and uptake of LDEVs by HFBs. (Han, et al. 2023)

FAQs

Q: How do you handle endotoxin in Gram-negative OMV production?

A: Gram-negative outer membrane vesicles inherently contain lipopolysaccharide (LPS). Our cosmetic-grade purification protocols apply multi-step endotoxin reduction including polymyxin B affinity chromatography, anion-exchange separation, and detergent-based LPS stripping, targeting residual endotoxin levels below 0.5 EU/mL. For strains where endotoxin cannot be reduced to cosmetic thresholds, we recommend transitioning to Gram-positive probiotic CMV platforms that lack LPS entirely.

Q: Can you produce mEVs from client-provided proprietary strains?

A: Yes. Client strains are accepted under confidentiality agreements with secure strain banking. We perform full safety profiling on every client strain before compliant production begins. Proprietary fermentation parameters and production protocols are documented for technology transfer, ensuring ingredient IP remains with the brand owner.

Q: What is the difference between cosmetic-grade and GMP-grade production?

A: Cosmetic-grade production meets cosmetic ingredient manufacturing standards with controlled fermentation, validated purification, defined purity thresholds, and regulatory documentation for INCI registration and safety assessment. GMP-Grade production adds pharmaceutical-level quality assurance including validated cleaning procedures, environmental monitoring, change control documentation, and QA release authority. Cosmetic-grade is sufficient for topical ingredient registration; GMP-grade is required for injectable or therapeutic claims.

Q: Do you provide stability testing for cosmetic ingredient registration?

A: Yes. We conduct real-time stability testing at 25°C/60% RH and accelerated stability testing at 40°C/75% RH per ICH-aligned conditions, monitoring particle retention, protein integrity, endotoxin stability, and sterility over defined time points. Stability data packages are formatted for inclusion in regulatory submissions supporting declared shelf-life claims.

Q: What INCI name conventions apply to microbial exosome ingredients?

A: INCI naming for microbial-derived vesicle ingredients follows the organism-based convention (e.g., “Lactobacillus ferment extracellular vesicles” or “Bifidobacterium lysate extracellular vesicles”). We assist clients in proposing appropriate INCI nomenclature and preparing the supporting documentation required for International Nomenclature Committee review and registration.

Q: How do you ensure batch-to-batch consistency for cosmetic ingredient supply?

A: Locked fermentation protocols, standardized purification sequences, and defined QC release criteria ensure reproducible batch output. Inter-batch CV ≤20% for particle concentration, size distribution, and key purity metrics across three consecutive production batches. Deviation investigations and corrective actions are documented per cosmetic ingredient quality management standards.

References:

Han, F., et al. (2023). Extracellular vesicles from Lactobacillus druckerii inhibit hypertrophic scar fibrosis. Journal of Nanobiotechnology, 21, 113.

Services

Inquiry